Simple blood draw could replace invasive biopsies for cervical cancer

NCT ID NCT05606133

Recruiting now Diagnosis Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a blood test called NavDx that looks for tiny pieces of HPV DNA shed by cancer cells. The goal is to see if this simple blood draw can accurately detect cervical cancer and precancer, and monitor how patients respond to treatment. The study will enroll 100 women with HPV-related cervical dysplasia or cervical cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NavDx blood test
What this could lead to: If successful, this blood test could provide a simple, non-invasive way to screen for and monitor cervical cancer and precancer, reducing the need for biopsies and other invasive procedures.
What could go wrong: This is a small pilot study with only 100 participants, so results may not apply to everyone. The test may not reliably distinguish between precancer and invasive cancer, and further larger studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical intraepithelial neoplasia dysplasia of cervix Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER CERVICAL DYSPLASIA

Contacts and locations

Locations

Lenox Hill Hospital
RECRUITING

New York, New York, 10075, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.